Organon Stock Skyrockets 28% Following Reports of $12 Billion Buyout Offer From Sun Pharma

Key Stats for Organon Stock

• Price change for Organon stock: 28%
• $OGN Share Price as of Mar. 10: $9
• 52-Week High: $13
• $OGN Stock Price Target: $9

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

What Happened?

Organon (OGN) stock surged roughly 28% on Friday after reports out of India indicated that Mumbai-based drugmaker Sun Pharmaceutical had submitted a $12 billion binding offer for the company.

• According to India’s Economic Times, Sun Pharma has completed more than three months of due diligence and is now finalizing deal financing with backing from JPMorgan and MUFG.
• If completed, the deal would be the largest overseas acquisition ever made by an Indian pharmaceutical company.
• Sun Pharma called the report “speculative in nature” but didn’t deny the process outright.
• Its own shares fell about 3% in reaction to the news — a typical market response when investors weigh the cost of a large acquisition on the buyer.

BNP Paribas analyst Navann Ty, who carries an Outperform rating on Organon stock, said the deal could make sense for both sides.

At a $12 billion enterprise value, Ty estimates the implied offer price could reach around $15 per share.

That would represent roughly 115% upside to where Organon stock closed before the news, and still sits 24% above BNP Paribas’s own $12 price target.

See analysts’ growth forecasts and price targets for Organon stock (It’s free) >>>

What the Market Is Telling Us About Organon Stock

Organon stock had been under significant pressure heading into this news. The company — spun out of Merck in 2021 — reported full-year 2025

• Revenue of $6.2 billion, down 3% year-over-year.
• Net leverage sits at approximately 4.3x, and
• Business has faced headwinds across several product lines, including Nexplanon in the U.S. and its international respiratory portfolio.
• The company is guiding for roughly flat revenue and adjusted EBITDA of about $1.9 billion in 2026.

Management has been focused on cutting costs, paying down debt, and protecting margins while its biosimilar franchise and newer assets like Vtama gradually ramp.

That backdrop makes Organon stock a logical acquisition target. The assets are stable, the global commercial infrastructure spans 140 countries, and the valuation had been beaten down before today’s move.

For Sun Pharma, buying Organon would represent a dramatic expansion of its international reach and branded product portfolio.

Whether the deal closes remains to be seen. But today’s rally makes clear that investors think the offer is credible — and that Organon stock may have been deeply undervalued before the market got wind of it.

Estimate a company’s fair value instantly (Free with TIKR) >>>

How Much Upside Does Organon Stock Have From Here?

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>

Looking for New Opportunities?

• See what stocks billionaire investors are buying so you can follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!